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Abstract
Background: Since the introduction of the orphan drugs legislation in Europe, it has been suggested that the
general method of assessing drugs for reimbursement is not necessarily suitable for orphan drugs. The National
Institute for Health and Clinical Excellence indicated that several criteria other than cost and efficacy could be
considered in reimbursement decisions for orphan drugs. This study sought to explore the multi-criteria decision
analysis (MCDA) framework proposed by (Orphanet J Rare Dis 7:74, 2012) to a range of orphan drugs, with a view
to comparing the aggregate scores to the average annual cost per patient for each product, and thus establishing
the merit of MCDA as a tool for assessing the value of orphan drugs in relation to their pricings.
Methods: An MCDA framework was developed using the nine criteria proposed by (Orphanet J Rare Dis 7:74, 2012)
for the evaluation of orphan drugs, using the suggested numerical scoring system on a scale of 1 to 3 for each
criterion. Correlations between the average annual cost of the drugs and aggregate MCDA scores were tested and
plotted graphically. Different weightings for each of the attributes were also tested. A further analysis was
conducted to test the impact of including the drug cost as an attribute in the aggregate index scores.
Results: In the drugs studied, the R2, that statistically measures how close the data are to the fitted regression line
was 0.79 suggesting a strong correlation between the drug scores and the average annual cost per patient.
Conclusion: Despite several limitations of the proposed model, this quantitative study provided insight into using
MCDA and its relationship to the average annual costs of the products.
Keywords: Multi-criteria decision analysis, MCDA, Orphan drugs, Reimbursement, Mucopolysaccharidosis II,
Paroxysmal nocturnal haemoglobinuria, Pulmonary arterial hypertension, Myelodysplastic syndromes, Lennox-
Gastaut syndrome
Background
In recent years, substantial criticism has arisen regarding
the way in which orphan drugs are reviewed in health tech-
nology assessments (HTAs), in particular with respect of
their inability to meet cost-effectiveness standards for reim-
bursement decisions [1]. In some countries, the orphan
drugs are reimbursed despite their lack of meeting cost-
effectiveness thresholds, yet in others, such as in Scotland,
reimbursement has been denied on the basis of a lack of
cost-effectiveness. For example, alglucosidase alfa was
refused reimbursement on the basis that “The economic
case has not been demonstrated” [2]. Information regarding
the cost-effectiveness of orphan drugs is derived from eco-
nomic evaluations, such as cost-effectiveness analyses or
cost-utility studies [3]. Such studies involve comparing the
new drug with the existing treatment options [4]. The
perceived advantage of the current HTAs – that includes
cost-effectiveness - is that they provide an output, the
incremental cost-effectiveness ratio (ICER) that is intended
to make the outcomes of the different technologies com-
parable across different diseases. However, there is concern
that valuing healthcare interventions mostly based on cost-
effectiveness is a form of healthcare rationing, in particular
since cost-effectiveness only takes two criteria (cost and
* Correspondence: carina@gmasoln.com
1Unit of PharmacoEpidemiology & PharmacoEconomics, Department of
Pharmacy, University of Groningen, Groningen, The Netherlands
2Global Market Access Solutions (GMAS), St-Prex, Switzerland
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Schey et al. Orphanet Journal of Rare Diseases  (2017) 12:10 
DOI 10.1186/s13023-016-0555-3
efficacy) into consideration, and that using the ICER may
limit the potential treatment options available to patients
by excluding potentially worthwhile alternatives [5]. For
example, in England, the National Institute for Health and
Care Excellence (NICE) has adopted a nominal cost-per-
QALY threshold of £20,000 to £30,000 [6]. However, if the
cost-effectiveness analysis of a drug yields a cost-per-QALY
that is substantially higher than the guide threshold, it
might be refused funding.
Furthermore, concern has been raised that because of
their costs, in addition to the frequent lack of suitable
comparators, and the difficulties of demonstrating robust
efficacy in small patient populations, orphan drugs are not
deemed (robustly) cost-effective under the standard
methods of HTA [1, 3]. This potentially results in patients
not having access to potentially valuable treatments [7].
While the debate regarding the applicability of cost-
effectiveness analysis for orphan drugs has been on-
going, multi-criteria decision analysis (MCDA) has been
suggested as an alternative to the standard HTA meth-
odology for assessing orphan drugs [8]. MCDA is a
methodology for supporting decision making when mul-
tiple objectives, aside from cost and efficacy, have to be
assessed [9]. For example, other aspects that may need
to be considered are the availability of alternative treat-
ments, disease prevalence and disease severity. MCDA
has been extensively used to support a wide variety of
complex decision problems in non-health industries,
such as geographic information systems [10], banking
and finance [11] and environmental policy issues for
many years [12]. In the last few years, interest in the use
of MCDAs in healthcare has increased. MCDA has been
adopted in a number of studies in healthcare [13–15].
MCDA has not yet been used exclusively in HTAs in
place of cost-effectiveness studies, although The National
Institute for Health and Care Excellence (NICE) and the
Scottish Medicines Consortium (SMC) in the UK occa-
sionally adopt an MCDA approach, in that they consider
cost-effectiveness as well as several other criteria [16, 17].
MCDAs provide a structured framework for the com-
parison of multiple options (or criteria) relating to a
drug or a disease. Through engagement with a broad
range of potential stakeholders, that can include clini-
cians, decision makers and the public, MCDAs allow the
different perspectives for the preferences of the criteria
and their relative importance in rare diseases to be taken
into account [18, 19]. Because MCDAs offer a number
of ways of aggregating the data of the individual criteria,
they inherently provide a system for ranking healthcare
interventions [20]. Through weighting the importance of
the different criteria, MCDAs allow for clear trade-offs
between various criteria [21, 22]. One of the main
points, and indeed part of the impetus for change by
health services, in particular the National Health Service
(NHS) in the UK, is the aim of including wider aspects
of social and economic value in healthcare assessments,
rather than to use “health gain” as the sole currency of
value in the NHS [23]. Because it is designed to consider a
broad set of criteria and their values, the MCDA offers a
framework that is robust, transparent and can be flexible in
assessing orphan drugs for different diseases [24, 25], and
in particular fills a current void in appropriate mechanisms
to assess the value of orphan drugs.
Considering the criticisms of existing HTA processes,
several attempts have been made at using alternative
methods to inform decision makers on the appropriate
allocation of healthcare funds. In 2012, Hughes-Wilson
et al. [8] developed an MCDA algorithm that assesses a
medicine based on multiple criteria. The aims of this
study were to apply the MCDA framework that was pro-
posed by Hughes-Wilson et al. [8] to a range of orphan
drugs in different diseases, with a view to testing the
relationship between drug price and aggregated MCDA
scores for each product.
Methods
MCDA Framework
An MCDA framework was developed using the nine
suggested criteria [8], which included: Rarity, level of
research undertaken, Level of uncertainty of effectiveness,
Manufacturing complexity, Follow-up measures, Disease
severity, Available treatment alternatives, Level of impact
of disease, and Unique indication or not. The Follow-up
measures refers to any additional requirements by regu-
latory or similar authorities. The Level of impact of
disease refers to the extent to which the new technology
impacts on the disease in question. Each of these criteria
are further described in Table 1.
Six orphan drugs were identified for the prototype
evaluation for which data were obtained from Summary
of Product Characteristics (SPC) and European public
assessment reports (EPAR). A literature search was per-
formed to identify relevant clinical trials for each of the
drugs. Data relating to the results for the criteria in-
cluded in the study were extracted. Furthermore, the
literature review included disease-specific peer-reviewed
publications and patient advocacy organisations to ex-
tract data relating to disease severity and the impact of
disease on patients.
The six drugs were selected for the study based on the
wide range of average annual cost per patient for each
drug, as well as the wide range of diseases which they
treat. Furthermore, some were included due to the con-
sistently negative media coverage they receive. The aver-
age annual cost is based solely on the cost of the drugs,
and therefore excludes any additional costs, such as
those related to administration of the drugs or any ancil-
lary items for intravenously administered drugs. These
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drugs were also selected to represent different degrees of
the rarity of the diseases they treat, based on the cat-
egorisation provided in the proposed framework on
which this study is founded. For example, a disease with
a prevalence of 1 per 2,000 to 1 per 20,000 population
(highest prevalence level) scored 1. The drugs included
are indicated for: Pulmonary arterial hypertension
(PAH), Mucopolysaccharidosis VI (MPS VI), Mucopoly-
saccharidosis II (MPS II), Paroxysmal nocturnal haemo-
globinuria (PNH), Lennox-Gastaut syndrome (LGS) and
Myelodysplastic syndromes (MDS).
Based on the scoring approach suggested [8], each cri-
terion was allocated a numerical score, from 1 to 3, where
1 indicated the lowest level of attribution allocated. This
simple numerical scoring system avoids the need for an
expert panel to score the different criteria. The average
dose per patient was calculated from product SPCs, taking
account of the dose variation for drugs that are used in
children (e.g. Mucopolysaccharidosis VI), versus those
most likely to be used only in adults (e.g. Myelodysplastic
syndromes) without any specific weighting of paediatric
versus adult use. Using the average dose, the average
annual cost per patient was calculated from published
prices in the British National Formulary (BNF) and con-
verted into Euros (January 2014 exchange rates). Due to
pricing confidentiality, official list prices were adopted for
the drugs included in this study. For the purposes of this
model, all drugs were assumed to be used routinely as
indicated in the SPC for a total of 1 year.
Analysis
The relationship between the average annual cost of
each drug and aggregate MCDA scores were tested and
plotted graphically. Weighting preferences, as tabulated
in Table 1, were applied to the different criteria to assess
how the results might differ. The weighting preferences
were not based on primary data collection but rather by
using 3 scenario tests. In the first scenario, all criteria
were weighted equally. In the second scenario, the
criteria of Level of Research Undertaken, Level of Effect-
iveness Uncertainty, Manufacturing Complexity and
Unique Indication or Not were excluded, on the basis
that these criteria are not likely to be considered by
HTA bodies. In the third scenario, only the criteria of
Manufacturing Complexity and Unique Indication or
Not were excluded from the analysis to establish how
inclusion of Level of Research Undertaken and Level of
Effectiveness Uncertainty might influence the outcomes
compared to Scenario 2 (Table 2).
Table 1 Description of criteria used in this study
Criteria Category Score












Immature but promising data 1
Appropriate surrogate endpoints 2
Robust clinical endpoints 3
Manufacturing
complexity
Not complex; small molecule 1
Moderately complex 2
Highly complex, biological and
galenic form
3
Follow-up measures Safety and efficacy studies, and size
and duration of study
1
Designed to answer specific, defined
delineated question
2
Moderate to none 3
Disease severity Morbidity 1
Mortality, severe invalidity in adulthood 2
Mortality/severe invalidity as an infant 3
Available alternatives/
Unmet needs
Alternatives with similar characteristics 1
Alternatives - but this offer strong










Existing orphan or non-orphan indication
for the same molecule
1
Potential for multiple indications 2
Unique indication. No other possible use 3 Table 2 Scenario testing with weights applied to each criterion
Criteria Weights applied in each scenario
Scenario 1
(Base Case)
Scenario 2 Scenario 3
Rarity 11.1% 14.0% 10.0%
Level of research undertaken 11.1% 0.0% 20.0%
Level of effectiveness uncertainty
(robustness of endpoints)
11.1% 0.0% 10.0%
Manufacturing complexity 11.1% 0.0% 0.0%
Follow up measures or Monitoring 11.1% 6.0% 15.0%




Level of impact on disease
(Disease modification)
11.1% 30.0% 20.0%
Unique indication or not 11.1% 0.0% 0.0%
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Results
The overall scores achieved for each drug, including
the contribution of the individual criteria scores to
the total are depicted in Fig. 1. The drug scores were
plotted against the average annual cost per patient for
each drug as shown in Fig. 2. In the drugs studied,
the R2 was 0.7869 suggesting a strong correlation be-
tween the drug scores and the average annual cost
per patient. In other words, the higher the drug’s
aggregate score, the more likely it was to have a high
average per patient cost.
The scenario analyses demonstrate that by applying
different weights to the criteria, the ranking of the drugs
change, in particular, for those drugs whose average
annual cost per patient features on the higher end of the
scale (Fig. 3).
Discussion
This study sought to test the MCDA framework pro-
posed by Hughes-Wilson et al. [8] to establish if such a
simple framework, both in the suggested criteria and the
simplistic scoring system, could be used to inform in
decision making in the reimbursement of drugs. MCDA
is a framework that through the choice of appropriate
criteria, can assist decision makers in healthcare. We
believe that although the suggested framework provided
a tool worth testing, and provided initial insights into
the application of MCDA as a method of assessing
orphan drugs, it did not capture some of the essential
criteria. This might be because the proposed framework
may have been developed from a pharmaceutical com-
pany perspective, since it is unlikely that a HTA body
would consider Manufacturing complexity and the
Fig. 1 Overall drug scores based on the proposed MCDA framework. PAH: Pulmonary arterial hypertension; MPS II: Mucopolysaccharidosis II; LGS:
Lennox-Gastaut syndrome; MPS VI: Mucopolysaccharidosis VI; PNH: Paroxysmal nocturnal haemoglobinuria; MDS: Myelodysplastic syndromes
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Fig. 2 The total drug score in relation to the average annual cost (€) based on UK list prices. PAH: Pulmonary arterial hypertension; MPS II:
Mucopolysaccharidosis II; LGS: Lennox-Gastaut syndrome; MPS VI: Mucopolysaccharidosis VI; PNH: Paroxysmal nocturnal haemoglinuria; MDS:
Myelodysplastic syndromes
Fig. 3 Scenario testing of the criteria with different weighting applied in each scenario. Note: Criteria excluded in Scenario 2: Level of research
undertaken; Level of effectiveness uncertainty; Manufacturing complexity; Unique indication or not. Criteria excluded in Scenario 3: Manufacturing
complexity; Unique indication or not. PAH: Pulmonary arterial hypertension; MPS II: Mucopolysaccharidosis II; LGS: Lennox-Gastaut syndrome; MPS VI:
Mucopolysaccharidosis VI; PNH: Paroxysmal nocturnal haemoglinuria; MDS: Myelodysplastic syndromes
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Unique indication or not for which a drug is licensed as
relevant criteria when assessing orphan drugs for reim-
bursement decisions.
Furthermore, other important limitations of this MCDA
framework would need to be addressed before MCDA
frameworks could be considered. One such limitation is
the scoring system that was proposed and therefore
adopted. It is a simplistic numerical scoring system from 1
to 3 that implies that a change in a criterion from a score
of 1 carries the same value as the change from a score of 2
to 3. Similarly, the proposed framework did not allow for
weighting of the criteria, yet in reality it can be anticipated
that criteria should be weighted differently to accommo-
date the degree of importance of criteria.
A further limitation of the study is that the scenario
testing adopted in this study excluded those criteria such
as Level of Research Undertaken, Level of Effectiveness
Uncertainty, Manufacturing Complexity and Unique
Indication or Not. Whilst this was done on the basis that
these criteria are not likely to be taken into account by
HTA bodies, it limits the number of criteria that are
then reflected fully. Whilst this proposed framework
may inform in the decision making for orphan drugs, it
does not offer insights for comparing resource allocation
of orphan drugs with non-orphan drugs. Future MCDA
frameworks should include a broader range of criteria
that better reflect the Efficacy and Safety of the drugs.
This may potentially lead to MCDA frameworks being
disease-specific so that Efficacy can be captured in relation
to the disease. The downside of such a framework how-
ever, would be that it would not allow for comparisons of
drugs across different therapy areas.
One of the criticisms of current HTA cost-effectiveness
analyses is that these are largely viewed from a healthcare
perspective, and may fail to include the patient and soci-
etal perspectives [26]. This also raises questions as to
whether MCDA should be applied from a single perspec-
tive or whether attributes can reflect varied perspectives.
Future MCDA models could potentially include criteria to
represent multiple perspectives, that will allow for several
additional analyses of the impact of criteria on decision
making.
Since resources in healthcare at both the public and pri-
vately funded levels are scarce, cost-effectiveness analyses
have been adopted in decision making to ensure the effi-
cient use of finite resources with a view to maximising
health benefits [27, 28]. This intention of the proposed
MCDA framework [8] was to suggest a robust way for
decision makers to conduct a comparative assessment of
orphan drugs. However, the authors of the proposed
MCDA framework did not suggest how the tool could be
used to address issues of healthcare resource allocation.
We would expect that the use of MCDA will first have to
undergo further studies and an adjudication or
validation process, and that it is likely that MCDA
composite score thresholds of affordability and health-
care resource efficiency might be used.
We had aimed to compare the composite scores for
each of the drugs with published ICERs as a way of
establishing if parallels could be drawn between the two
sets of data. However, due to the paucity of published
ICERs for all six drugs in the same country, we were
unable to perform this comparison. We suggest that
future MCDA frameworks take ICERs into account as
an external “validation”.
Increasingly MCDA tools are being developed for
healthcare purposes. For example, The Evidence and
Value: Impact on Decision Making (EVIDEM) group
proposed a “core” MCDA framework for use in health-
care [29]. The aim of the EVIDEM framework is to
support the prioritisation of a broad range of healthcare
interventions, such that priority is given to the interven-
tion that obtains the highest rank. Because the EVIDEM
MCDA model was developed for a wide range of health-
care decisions (including services, products, drugs) it is
a complex model with far more criteria than the MCDA
framework adopted in this study.
The region of Lombardia in Italy has adopted an
MCDA approach to regulate the introduction of new
health technologies. Their MCDA is based on the EVIDEM
framework. The introduction of this formal MCDA model
stemmed from the desire to balance goals of continuous
innovation with the needs of steady cost containment, and
to instill uniformity and transparency in a process that may
be highly complex. While subjectivity cannot be completely
removed, the framework seeks to minimise discretion in
decision making and to produce decisions perceived as
legitimate by all the stakeholders [30]. The EVIDEM
framework has also been used in Canada by healthcare
payers, in a way of bridging MCDA with health tech-
nology assessments [31].
Since many rare diseases can have severe conse-
quences on health and health-related quality of life [32],
Disease Severity is a criterion of substantial importance
in assessing the benefits of orphan drugs on health-related
outcomes in patients. Although one would expect Disease
Severity to influence reimbursement decision-making, its
application in reimbursement decisions is not widely
known. By contrast, the MCDA tool allows for consider-
ation of the severity of a disease. Because of the often
complex nature of rare diseases, we believe that Disease
Severity should be sub-divided into 4 sub-criteria of
Disease-related mortality, How symptomatic the disease is,
Mental status (anxiety / depression), Physical implications
and/or disability.
The criterion Unmet Need is one that deserves further
clarification for its application in MCDA. Whilst the
framework does not allow for it to have sub-criteria, we
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feel that the unmet need in a disease is not only
dependent on the number of other available drugs for
the disease, but also the benefit that is likely to be gained
from the alternative treatment(s). In the highly specia-
lised technology (HST) guidance in England, NICE does
consider the Unmet need when assessing drugs for very
rare conditions [33]. In The Netherlands, the ministry
introduced a temporary scheme for orphan drugs, that
recognises both the lack of cost-effectiveness data and
the high unmet need that new orphan drugs address
[34]. Similarly, the criterion Level of research under-
taken is simplified, and we believe that it should reflect
the three sub-criteria of Level of trials undertaken, Trial
duration, Size of trial.
A criterion that we would recommend in future
MCDA models is Treatment Convenience. Our rationale
for this suggestion is that since some drugs may need to
be administered regularly by non-oral routes i.e injection
or intravenously, these may impact significantly on over-
all treatment costs, an aspect of treatment worth includ-
ing in drug assessments. Taking account solely of the
drug cost is not an accurate reflection of the total cost
of a patient’s treatment.
We appreciate that the framework proposed by Hughes-
Wilson et al. [8] was intended as a basic starting point for
the adoption of MCDAs in assessing orphan drugs. How-
ever, its simplicity fails to capture a key criterion that
HTA bodies would consider, in particular that of Safety.
Following further research, we recommend that Safety
should be divided into 3 sub-criteria that include Serious
adverse events (in clinical trials), Drug discontinuation
due to adverse events, and Treatment-related mortality.
A simple ordinal scoring system was applied in this
model, with equal importance between grades. Despite
potential criticism about the imprecision of a simple
numerical scoring system, the rationale for its use is due
to its simplicity and that it does not require an expert
panel to adjudicate the value of one criterion against
another, as would be the case in outranking methods
[35], satisficing methods [36] and value measurement
methods [36]. Furthermore, it does not require the use
of special computer software.
In this exploration of the proposed MCDA model, we
adopted simple scenario testing to measure the impact
of weighting the criteria differently. Although the 3
scenarios demonstrated a slight difference in the ranking
of the drugs, weighting is none the less a feature of
MCDAs that requires further investigation. A recent
publication [37] which was identified in the literature
review examined eight weighted criteria that were con-
sidered important for orphan drug approvals. These
were categorised by either the Impact of disease/extend
of unmet medical need, which included Availability of
existing treatment, Disease survival prognosis with current
standard of care (SOC), Disease morbidity and patient
clinical disability with current SOC, Social impact of
disease on patients’ and carers’ daily lives with current
SOC, or the Impact of new medicine, which considered
the criteria of Treatment innovation, Evidence of treat-
ment efficacy, Evidence of treatment safety, Social impact
on treatment on patients’ and carers’ daily lives. The 8
criteria were weighted in different scenarios by two
groups, of which one were “clinical/economic experts”
and the other were patient advocates. The clinical/eco-
nomic experts put more weight on efficacy, whereas the
patient advocates weighed treatment efficacy and impact
on daily lives equally. While the scenario testing proved
insightful, it is worth noting that some of the criteria
included in the study would not necessarily be ones that
HTA bodies consider, such as those that focus on the
social aspects of the rare disease and the social impact of
the new drug. Due to the differences in the criteria consid-
ered in the aforementioned study [37], we felt that we
could not adopt their weighting preferences in testing our
model. However, any weighting that might be applied to a
MCDA model can be tailored by an HTA body or decision
maker to reflect local preferences.
The R-squared value of 0.7869, the response variable
variation that is explained by a linear model, suggests a
good correlation between the average annual cost per
patient and each drug’s aggregate score. This implies
that as the MCDA score per drug increases, so does the
average annual cost. However, there are limitations to
using R-squared in that it cannot determine whether or
not the coefficient estimates and predictions are biased.
Additional regression analyses should be included in
future studies on MCDAs to test the best-fit.
It would be ideal to subject a new method or model
for assessing drugs, irrespective of the perspective from
which it is conducted, to an external process of valid-
ation. To the best of our knowledge, the framework that
the authors proposed [8] has not been tested nor vali-
dated. At this point, the proposed model is conceptual
and would be subjected to validation once the criteria
and other aspects, such as the methodology pertaining
to the scoring and weighting, have been refined.
A drawback of MCDA frameworks is that they do not
inform on the budget impact of the drugs in question.
However, it is fair to point out that cost-effective ana-
lyses that report on ICERs also do not express the
budgetary impact and consequently do not inform on
the viability of adopting a new technology from the
healthcare system perspective [38, 39]. We suggest that
when developing MCDA tools in the future, it might be
appropriate to include a criterion to assess the budget
impact, based on the likely patient population that
would be treated with each drug in the health economy
for which the tool is developed. This process could be
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standardised by using the budget impact template pro-
vided by the Scottish Medicines Consortium [40].
In the future, a key criterion that should be included
in MCDAs is the health-related quality of life (HRQoL),
which is frequently reported on in clinical trials, and
which is likely to reflect the impact of the disease and
new treatment on the patients than the social aspects
captured by Sussex et al. [37].
Conclusion
The framework proposed by Hughes-Wilson et al. [8]
has provided a small insight into the application of
MCDAs to orphan drugs. At the time of this study, the
ISPOR MCDA Task Force reports and guidelines had
not been published, and in future these should be closely
considered. It is worth noting that several other criteria
would offer additional insights to the overall product
aggregate. In a market constrained by costs, a product
aggregate score that includes criteria for innovation and
HRQoL could assist decision makers considerably. The
strength of MCDAs in reimbursement decisions for
orphan drugs is that they provide transparency and
robustness, and unlike traditional HTA methods, assess
more than merely cost-effectiveness. Defining the cri-
teria at the outset is crucial to ensure that overlap
between criteria is avoided. Furthermore, it is essential
that the criteria are not selected merely to favour a pre-
ferred outcome. Weighting the criteria may be compli-
cated, and dependent on the perspective of the assessment
[41]. Future work will include research to understand
the weights of different criteria and how they affect
the outcomes; and to compare HTA decisions with
MCDA outcomes.
Literature search terminology
“orphan drug”, “multi-criteria decision analysis”, “MCDA”,
“MCDA+healthcare”, “multi-criteria decision analysis +
healthcare”, “multi-criteria decision analysis + orphan drug”
Abbreviations
BNF: British National Formulary; EPAR: European public assessment reports;
HRQoL: Health-related quality of life; HST: Highly specialised technology;
HTA: Health technology assessment; ICER: Incremental cost-effectiveness
ratio; LGS: Lennox-Gastaut syndrome; MCDA: Multi-criteria decision analysis;
MDS: Myelodysplastic syndromes; MPS II: Mucopolysaccharidosis II; MPS
VI: Mucopolysaccharidosis VI; NHS: National Health Service; NICE: National
Institute for Health and Care Excellence; PAH: Pulmonary arterial
hypertension; PNH: Paroxysmal nocturnal haemoglobinuria; SMC: Scottish




No funding was made and no payment was received for this research.
Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or
analysed during the current study.
Authors’ contribution
CS was involved in the conception and design of the MCDA model, and
carried out the analyses and interpretation of the data, in addition to
drafting the manuscript. MC reviewed the model and manuscript. MP and PK
contributed to the design of the model and writing of the manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests. Prof Maarten J
Postma has received grants and honoraria from various pharmaceutical
companies in the past but unrelated to this manuscript.
Consent for publication
All co-authors have consented to publication of this manuscript. No person’s
data has been included in this study.
Ethics approval and consent to participate
Ethics approval was not required as no animals nor humans were involved
in this study.
Author details
1Unit of PharmacoEpidemiology & PharmacoEconomics, Department of
Pharmacy, University of Groningen, Groningen, The Netherlands. 2Global
Market Access Solutions (GMAS), St-Prex, Switzerland. 3Department of
Epidemiology, (UMCG), University of Groningen, University Medical Center
Groningen, Groningen, The Netherlands. 4Institute for Science in Healthy
Aging & healthcaRE (SHARE), UMCg, University of Groningen, Groningen, The
Netherlands.
Received: 24 September 2016 Accepted: 14 December 2016
References
1. Drummond MF. Assessing the economic challenges posed by orphan
drugs. Int J Technol Assess Health Care. 2007;23(1):36–42.
2. Scottish Medicines Consortium. Alglucosidase alfa (Myozyme®): https://
www.scottishmedicines.org.uk/SMC_Advice/Advice/alglucosidase_alfa_
50mg_powder__Myozyme___352-07_/alglucosidase_alfa__Myozyme____
352-07_. Accessed Apr 2016
3. Picavet E, Cassiman D, Simoens S. What is known about the cost-
effectiveness of orphan drugs? Evidence form cost-utility analyses. J Clin
Pharm Ther. 2015;40:304–7.
4. Sorenson C, Drummond M, Kanavos P. Ensuring value for money in
healthcare. The role of health technology assessment in the European
Union. European Observatory on Health Systems and Policies. 2008:
http://www.euro.who.int/__data/assets/pdf_file/0011/98291/E91271.pdf.
Accessed Mar 2016
5. Cleemput I, Neyt M, Thiry N, De Laet C, Leys M. Using threshold values for
cost per quality-adjusted life-year gained in healthcare decisions. Int J
Technol Assess Health Care. 2011;27(1):71–6. http://www.eurohex.eu/
bibliography/pdf/Cleemput_2011-2235638016/Cleemput_2011.pdf.
Accessed Mar 2016.
6. Appleby J, Devlin N, Parkin D. NICE’s cost effectiveness threshold. BMJ.
2007;335:358–9.
7. Cohen JP, Felix A. Are payers treating orphan drugs differently? J Market
Access Health Policy. 2014;2:23513. http://www.jmahp.net/index.php/jmahp/
article/download/23513/31873.
8. Hughes-Wilson W, et al. Paying for the orphan drug system: break or bend?
Is it time for a new evaluation system for payers in Europe to take account
of new rare disease treatments? Orphanet J Rare Dis. 2012;7:74. http://www.
ojrd.com/content/7/1/74. Accessed Oct 2013.
9. Belton V, Stewart TJ. Multiple criteria decision analysis: an integrated
approach. Dordrecht: Kluwer; 2002.
10. Carver SJ. Integrating multi-criteria evaluation with geographical
information systems. Int J Geogr Inf Syst. 1991;5(3):321–39.
11. Hallerbach W, Spronk J. The relevance of MCDM for financial decisions. J
Multi-Criteria Decis Anal. 2003;11(4/5):187–95.
12. Linkov I, Moberg E. Multi-criteria decision analysis: environmental
applications and case studies. 2013. CRC Press. Taylor & Francis Group. ISBN
9781439853184 - CAT# K12453.
Schey et al. Orphanet Journal of Rare Diseases  (2017) 12:10 Page 8 of 9
13. Youngkong S, Teerawattananon Y, Tantivess S, Baltussen R. Multi-criteria
decision analysis for setting priorities on HIV/AIDS interventions in
Thailand. Health Res Policy Syst. 2012;10:6. http://www.ncbi.nlm.nih.gov/
pmc/articles/PMC3310796/.
14. Baltussen R, Mikkelsen E, Tromp N, Hurtig A, Byskov J, Olsen O, Baeroe
K, Hontelez JA, Singh J, Norheim O. Balancing efficiency, equity and
feasbility of HIV treatment in South Africa – development of
programmatic guidance. Cost Eff Resour Alloc. 2013;11:26. http://www.
resource-allocation.com/content/11/1/26.
15. Angelis A, Kanavos P. Applying Multiple Criteria Decision Analysis (MCDA) in
the context of HTA: an experimental case study on metastatic colorectal
cancer. J Pharm Policy Pract. 2015;8 Suppl 1:O8. http://www.ncbi.nlm.nih.
gov/pmc/articles/PMC4602173/. Accessed Mar 2016.
16. National Institute for Health and Care Excellence. NICE to assess high cost
drugs for rare conditions: https://www.nice.org.uk/News/Article/nice-to-
assess-high-cost-drugs-for-rare-conditions. Accessed Mar 2016
17. Barham L. Orphan Medicines. Special Treatment required? 2020 Health.org:
http://socialwelfare.bl.uk/subject-areas/services-activity/health-services/
2020health/147277orphan_medicines_2012.pdf. Accessed Mar 2016
18. Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, Longrenn T,
Mussen F, Peacock S, Watkins J, Ijzerman M. Multiple criteria decision
analysis for health care decision making—An introduction: report 1 of the
ISPOR MCDA emerging good practices task force. Value Health. 2016;19:1–
13. https://www.ispor.org/Multi-Criteria-Decision-Analysis-guideline.pdf.
Accessed Mar 2016.
19. Simoens S. Market access of orphan drugs and the role of multi-criteria
decision making. Orphanet J Rare Dis. 2012;7 Suppl 2:A26. http://www.ncbi.
nlm.nih.gov/pmc/articles/PMC3504597/. Accessed Mar 2016.
20. Johri M. Can Cost-Effectiveness Analysis Integrate Concerns For Equity?
Systematic Review. Int J Technol Assess Health Care. 2012;28(2):125–32.
21. Baltussen R, Niessen L. Priority setting of health interventions: the need for
multi-criteria decision analysis. Cost Eff Resour Alloc. 2006;4:14.
22. Wahlster P, Goedghebeur M, Kriza C, Niederlander C, Kolominsky-Rabas P,
and on behalf of the National Leading-Edge Cluster Medical Technologies
“Medical Valley EMN”. BMC Health Services Research201515:262: http://
bmchealthservres.biomedcentral.com/articles/10.1186/s12913-015-0930-0.
Accessed Mar 2016
23. Orr S, Wolff J, Morris S. What Values Should Count in HTA for New
Medicines under Value Based Pricing in the UK? UCL Centre for Philosophy,
Justice and Health. 2011: https://www.ucl.ac.uk/health-humanities/docs/
mcda.pdf. Accessed Mar 2016.
24. Angelis A, Kanavos P. Value-based assessment of new medical technologies:
towards a robust methodological framework for the application of multiple
criteria decision analysis in the context of health technology assessment.
PharmacoEconomics. 2016;34:435–46. http://eprints.lse.ac.uk/65148/1/
Angelis_Value-based%20assessment.pdf. Accessed Mar 2016.
25. Adlunlin G, Diaby V, Montero AJ, Xiao H. Multicriteria decision analysis in
oncology. Health Expect. 2015;18(6):1812–26.
26. Drummond M, Tarricone R, Torbica A. Assessing the added value of health
technologies: reconciling different perspectives. Value Health. 2013;16:S7–13.
http://www.valueinhealthjournal.com/article/S1098-3015(12)04158-7/pdf.
Accessed Jan 2016.
27. Sculpher M. Evaluating the cost-effectiveness of interventions designed to
increase the utilization of evidence-based guidelines. Fam Pract. Oxford
University Press. 2000;17 Suppl 1:S26–31.
28. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya DB, Evans
DB, Murray CJL. Making Choices in Health: WHO Guide to cost-effectiveness
analysis: http://www.who.int/choice/publications/p_2003_generalised_cea.
pdf. Accessed Sept 2016
29. Evidence and Value: Impact on Decision Making (EVIDEM). EVIDEM 2.3.
Decision Criteria: https://www.evidem.org/docs/2014/EVIDEM-v2-3-Decision-
criteria-2013-12-24.pdf. Accessed Jan 2016
30. Radaelli G, Lettieri E, Masella C. Implementation of EUNETHA core model® in
Lombardi: The VTS Framework. Int J Technol Assess Health Care. 2014;30(1):
105–12.
31. Tony M, Wagner M, Khoury H, Rindress D, Papastavros T, Oh P,
Goetghebeur MM. Bridging health technology assessment (HTA) with
multicriteria decision analyses (MCDA): field testing of the EVIDEM
framework for coverage decisions by a public payer in Canada. BMC
Health Serv Res. 2011;11:329. http://www.biomedcentral.com/1472-6963/
11/329. Accessed Nov 2015.
32. Wasfelt M, Fadeel B, Henter J. A journey of hope: lessons learned from
studies on rare diseases and orphan drugs. J Intern Med. 2006;260(1):1–10.
http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2796.2006.01666.x/pdf.
Accessed July 2014.
33. NICE highly specialised technologies guidance: https://www.nice.org.uk/
about/what-we-do/our-programmes/nice-guidance/nice-highly-specialised-
technologies-guidance. Accessed Mar 2016
34. Boon W, Martins L, Koopmanschap M. Governance of conditional
reimbursement practices in the Netherlands. Health Policy. 2010;
119(2):180–5.
35. Mousseau V, Dias L. Valued outranking relations in ELECTRE providing
manageable disaggregation procedures. Eur J Oper Res. 2004;156:476–82.
36. Thokala P, Duenas A. Multiple criteria decision analysis for health
technology assessment. Value Health. 2012;15:1172–81.
37. Sussex J, Rollet P, Garau M, Schmitt C, Kent A, Hutchings A. A pilot study of
multicriteria decision analysis for valuing orphan medicines. Value Health.
2013;16(8):1163–9.
38. Birch S, Gafni A. Information created to evade reality (ICER) – things we
should not look to for answers. Pharmacoeconomics. 2006;24:1121–31.
39. Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of
the lambda. Soc Sci Med. 2006;62:2091–100.
40. Scottish Medicines Consortium. Templates /Guidance for Submission.
Budget Impact Template: https://www.scottishmedicines.org.uk/
Submission_Process/Submission_guidance_and_forms/Templates-Guidance-
for-Submission/Templates-Guidance-for-Submission. Accessed Nov 2016
41. Expert Roundtable. Expert Roundtable on HTA of Orphan Drugs. 2012.
Facilitated by Shire Pharmaceuticals: https://www.yumpu.com/en/
document/view/30976389/expert-roundtable-on-hta-of-orphan-drugs-shire.
Accessed Oct 2015
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Schey et al. Orphanet Journal of Rare Diseases  (2017) 12:10 Page 9 of 9
